92 related articles for article (PubMed ID: 9668390)
1. Monosialoganglioside increased the in vivo affinity of D2 receptors for apomorphine in supersensitive rats.
Vital MB; Frussa-Filho R; Palermo-Neto J
Ann N Y Acad Sci; 1998 Jun; 845():428-9. PubMed ID: 9668390
[No Abstract] [Full Text] [Related]
2. Kinetic analysis of GM1 effects on haloperidol-induced dopaminergic supersensitivity.
Palermo-Neto J; Frussa-Filho R; Vital MA
Gen Pharmacol; 1999 Feb; 32(2):265-70. PubMed ID: 10188630
[TBL] [Abstract][Full Text] [Related]
3. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
[TBL] [Abstract][Full Text] [Related]
4. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
5. Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover.
Vital MA; Flório JC; Frussa-Filho R; De Lucia R; Tufik S; Palermo-Neto J
Life Sci; 1998; 62(13):1161-9. PubMed ID: 9519797
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
Schröder U; Schröder H; Augustin W; Sabel BA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
[TBL] [Abstract][Full Text] [Related]
7. Brexpiprazole has a low risk of dopamine D
Amada N; Akazawa H; Ohgi Y; Maeda K; Sugino H; Kurahashi N; Kikuchi T; Futamura T
Neuropsychopharmacol Rep; 2019 Dec; 39(4):279-288. PubMed ID: 31487433
[TBL] [Abstract][Full Text] [Related]
8. Drug effects on pre- and postsynaptic dopamine receptors.
Andén NE; Grabowska-Andén M
Adv Biochem Psychopharmacol; 1980; 24():57-64. PubMed ID: 6105802
[No Abstract] [Full Text] [Related]
9. Sensitivity of dopamine D2 receptors following long-term treatment with roxindole.
Seyfried CA; Bartoszyk GD
Eur J Pharmacol; 1994 May; 257(1-2):67-72. PubMed ID: 7915991
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic haloperidol, thioridazine and zotepine treatment on apomorphine elicited stereotypic behavior and 3H-spiroperidol binding sites in the striatum of the rat.
Lai HC; Carino MA; Horita A
Proc West Pharmacol Soc; 1981; 24():5-6. PubMed ID: 6114496
[No Abstract] [Full Text] [Related]
11. Effects of monosialoganglioside on dopaminergic supersensitivity.
Vital MA; Frussa-Filho R; Palermo-Neto J
Life Sci; 1995; 56(26):2299-307. PubMed ID: 7791517
[TBL] [Abstract][Full Text] [Related]
12. Kinetic analysis of central nervous system supersensitivity induced in rats by long-term haloperidol administration. I. pA2 determination.
Palermo-Neto J; Bernardi MM; Saban R
Pharmacology; 1984; 28(4):203-10. PubMed ID: 6539476
[TBL] [Abstract][Full Text] [Related]
13. Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
Seeman P
Schizophr Res; 2009 Apr; 109(1-3):191-2. PubMed ID: 19171464
[No Abstract] [Full Text] [Related]
14. Blockade of central dopaminergic receptors of morphine: effect of haloperidol, apomorphine or benztropine.
Puri SK; Reddy C; Lal H
Res Commun Chem Pathol Pharmacol; 1973 Mar; 5(2):389-401. PubMed ID: 4735501
[No Abstract] [Full Text] [Related]
15. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
16. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
Gnegy M; Uzunov P; Costa E
J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
[No Abstract] [Full Text] [Related]
17. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
Gulati A; Srimal RC; Dhawan BN
Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
[TBL] [Abstract][Full Text] [Related]
18. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
De Veaugh-Geiss J; Devanand DP; Carey RJ
Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
[TBL] [Abstract][Full Text] [Related]
19. Prolonged pharmacologic activity of neuroleptics.
Campbell A; Baldessarini RJ
Arch Gen Psychiatry; 1985 Jun; 42(6):637. PubMed ID: 2860886
[No Abstract] [Full Text] [Related]
20. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
